Kamada Ltd., a global biopharmaceutical company, expects to achieve 13% revenue growth and 23% adjusted EBITDA growth in 2026, projecting revenue between $200 million and $205 million and adjusted EBITDA between $50 million and $53 million. This growth is entirely organic, stemming from the company's proprietary specialty plasma therapies business and its distribution segment, which commercializes third-party biopharmaceutical products. The company is also on track to meet its 2025 targets, with revenue anticipated between $178 million and $182 million and adjusted EBITDA between $40 million and $44 million, ending the year with approximately $75 million in cash. Kamada plans to publish its 2025 financial results in the first half of March.
Amir London, Kamada's Chief Executive Officer, stated that the company enters 2026 from a position of significant commercial and financial strength, driven by organic growth from its diverse commercial product portfolio marketed in over 30 countries. Growth in 2026 will be fueled by increased sales in the U.S. market and higher sales of products like KAMRAB®, GLASSIA®, HEPAGAM®, and VARIZIG® in international markets. The distribution segment is also expected to contribute, particularly with the launch of additional biosimilar products in Israel and expansion into the Middle East and North Africa region. For more details on Kamada's financial filings, visit https://www.sec.gov.
Plasma collection at Kamada's Texas-based centers will further drive sales, with three centers operational in Houston and San Antonio. Each site has an annual collection capacity of about 50,000 liters of plasma, contributing an estimated $8 million to $10 million in revenue at full capacity. By developing its own plasma collection capabilities, Kamada reduces dependency on third-party suppliers and positions itself as a supplier for industry peers. The company's Kamada Plasma unit is one of a limited number of specialty plasma collection firms in the U.S., enhancing its competitive edge.
This projected growth is notable as it comes despite reduced GLASSIA royalty payments from Takeda Pharmaceutical Co. Ltd., with 2026 being the first full year under a lower rate. London emphasized that this demonstrates the company's resilience and strength. Beyond organic growth, Kamada is focused on new business development deals and acquisitions to enrich its product portfolio and generate synergies with existing commercial operations. The company's forward-looking statements, which include expectations for double-digit revenue growth and expansion initiatives, are subject to risks such as geopolitical conflicts and regulatory delays, as detailed in its SEC filings. The original release can be viewed on https://www.newmediawire.com.
